UCB acquires Candid Therapeutics in $2.2 billion deal

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune ...
BioSpace

AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...
FiercePharma

UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi

Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed ...

UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial

AbbVie (ABBV) stock is in focus as UCB's Bimzelx beats the company's immunology blockbuster Skyrizi in head-to-head trial for ...
FiercePharma

UCB's psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay

After a manufacturing-related complete response letter held up the U.S. launch of UCB’s psoriasis med bimekizumab last May, the FDA has officially closed out its inspection of the company's plant in ...
Pharmaceutical Technology on MSN

UCB doubles down on TCEs with $2.2BN Candid buyout

This acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE ...